Chinese Pharmaceutical Market: Forecasts and Outlooks 2014-2024

LONDON, July 29, 2014 /PRNewswire/ --

Medical revenues in China- your guide to trends, companies and potentials
What's the outlook for the Chinese pharma market? Can it sustain high growth? Visiongain's updated report gives you forecasted revenues there to 2024. That work explains medical and technological trends, prospects and commercial opportunities.

China still holds great potential for medicines and their sales. Our study gives data and predictions for that industry and market. You investigate activities of domestic and international companies - pharma and contract - and assess their environment.

That new analysis shows the most lucrative parts of Chinese healthcare. Read on to explore that market and see what its future could be worth to pharma industries.

Forecasts and other analyses to help you stay ahead for Chinese medical business
Our report gives you revenue predictions to 2024, historical data, growth rates and market shares. It lets you discover business outlooks, including research and development (R&D). You also gain 87 tables, 117 charts and four interviews.

Is finding data on Chinese healthcare proving difficult? Now you can stay ahead in knowledge, benefiting your research, analyses and decisions. The following sections explain.

Sales predictions for the Chinese drug market and its segments - discover potentials
Along with revenue prediction for the overall Chinese pharma market, you see individual forecasting to 2024 for these main submarkets:
• Hospitals
• Retail pharmacies
• Sales via other channels, including over-the-counter (OTC) products
• Small-molecule pharmaceuticals - with sub forecasts for novel and generic drugs
• Biological drugs - with sub forecasts for novel and biosimilar biologics, and for vaccines
• Traditional Chinese medicines (TCM).

Our study also gives individual revenue forecasts to 2024 for sales by therapeutic area:
• Infectious diseases - with sub-forecasts for antibacterial drugs (antibacterials), vaccines and antiviral agents (antivirals)
• Cancer - applications in oncology, anticancer agents
• Cardiovascular disorders - with sub-forecasts for hypertension and dyslipidaemia therapies
• Diabetes
• Respiratory diseases - with sub-forecasts for COPD and asthma treatments
• Autoimmune and inflammatory conditions
• Central nervous system (CNS) disorders - with sub-forecasts for antidepressants and antipsychotics
• Other medical needs (grouped).

Forecasts for contract research (CROs), manufacturing (CMOs) and sales (CSOs)
You also gain individual revenue forecasting to 2024 for these related industries in China:
• Contract medical sales
• Contract research - with sub forecasts for drug discovery and clinical trials outsourcing
• Contract manufacturing and other Chinese pharma production output - with division into drug formulations, active pharmaceutical ingredients (APIs), medical devices, TCM agents, and biologicals.

Also do you understand the changing market - expanding and widening needs? There our report helps you identify potential and find opportunities for revenue growth.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Epidemiological trends - find what patient needs underpin Chinese healthcare
Also for prominent diseases in China discover prevalence and incidences to 2025.
And get our patient flow models for diseases, seeing numbers of patients diagnosed, and treated cases predicted to 2024.

Also explore how companies serve those treatment needs:
• Number of clinical trials registered in China by phase
• Investigational new drug applications by therapy area
• Contract research organisations and their activities
• Chinese companies with innovative pharmaceutical developments
• Biotechnology there, including biomarker testing, regenerative medicine and stem cell research.

You also explore what influences Chinese healthcare industries and markets.

Characteristics, forces and issues affecting the Chinese pharma industry and market
Our report discusses issues, regulations and events affecting Chinese healthcare and related industries from 2014:
• Epidemiological trends, including effects of industrialisation and ageing population
• Sales outlets, distribution channels and product classes most important from 2014
• Manufacturing and R&D, including biotechnology and trends for venture capital
• Healthy China 2020 and other investments and reforms
• Healthcare funding - driving and restraining forces
• Opportunities in treating chronic diseases, including challenges of HIV and hepatitis.

That work also discusses other aspects of medical services and businesses in China, including these developments:
• The Anhui model
• Investment in rural healthcare - high demands needing served
• Growth of contract sales activities and other pharma outsourcing (inc. off-shoring)
• Branded generics - their prospects
• Biosimilar manufacturers - outlooks, including developing bio-betters.

That way you explore technological, economic, social and political trends. You also analyse that market's strengths, weaknesses, opportunities and threats for businesses. Discover what the future holds.

Leading drugs companies - domestic and foreign - and 2014 market value
What happens next? Our report predicts overall pharma sales in China will reach $97.4bn in 2014, expanding onwards to 2024. See what's possible.

The study covers these multinationals and others, with discussion of the top 10 big pharma companies operating in China:
• Bayer
• Pfizer
• AstraZeneca
• Roche
• Merck and Co.

Our work also discusses these domestic companies, and other top 30 firms based there:
• Yangtze Pharma
• Harbin Pharmaceutical
• Guangzhou Baiyunshan Pharmaceutical
• Kangmei Pharmaceutical
• Yunnan Baiyao.

In our study you find 320 organisations mentioned. Also you read our interviews with other authorities on Chinese pharma - you see opinions and discussions.

Prospects for product and service sales in China are strong, and from 2014 there will arise many opportunities for companies. Our work shows you the technological, medical and commercial possibilities, helping you succeed. Find that top emerging country's potential.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Ways Chinese Pharmaceutical Market: Forecasts and Outlooks 2014-2024 helps
In four main ways our investigation helps your work and authority:
• Revenues there to 2024 at overall national level and for 39 submarkets - assess outlooks for production, marketing and sales
• Epidemiology for China - see treatment needs by disease, assessing data on present and future trends
• Prospects for established competitors, rising companies and new entrants - explore results, R&D, news, technologies, activities and outlooks for success
• Interviews with authorities on China - scan opinions to help you stay ahead.

Information there found nowhere else, benefiting your knowledge and influence
That work gives independent analysis. There you receive competitive intelligence found only in our report, seeing where technological and financial prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses and decisions, also saving time and getting recognition for technological and commercial insight.

Our knowledge costs only a tiny fraction of potential profits from your understanding and harnessing the vast Chinese market. See its growth potential and find what you can gain.

Getting that report now lets you discover where the money lies in Chinese healthcare
That investigation is for everyone needing analysis of Chinese healthcare industries and markets. There you find data, trends, opportunities and predictions. Stay ahead, then - please get our new report here now.

To request an exec summary of this report please email Sara Peerun at            sara.peerun@visiongainglobal.com or call Tel : +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1298/Chinese-Pharmaceutical-Market-Forecasts-and-Outlooks-2014-2024

Companies Listed in this Report 

3SBio
Abbott Laboratories
Acambis
Advanced Biologics
Agilent
Alliance Boots
American California Pharmaceutical Group
AmerisourceBergen
Amgen
Anhui Anke Biotech
Anhui BBCA Biochemical
Astellas
AstraZeneca
AstraZeneca Innovation Center China
Asymchem Laboratories
Astellas
Aurobindo
AutekBiom
AXM Pharma
Bayer
BeiGene
Beijing Four Rings Bio-pharmaceutical
Beijing Genomics Institute
Beijing Kexing Bioproducts
Beijing Key Yuan Xinhai Pharmaceutical
Beijing Northland Biotech
Beijing SL Pharmaceuticals
Beijing Taiyang
Beijing Tiantan
Beijing Tiantan Biological Products
Beijing Tong Ren Tang
Beijing Union Medical College Hospital
Beijing University
Bio-Bridge Science
BioDura
Biotech Pharmaceutical
Boehringer Ingelheim
Broad Institute
Buchang Pharmaceutical
Cancer Foundation of China
Cancer Therapeutics
Cardinal Health
CASiGEN Pharma
Celgene
Celsion
Changzhou Qianhong Biopharma
Chemizon (Beijing) Pharma-Tech
Chengdu Di'ao Pharmaceutical Group
Chengdu Huasun Group
Chengdu Institute of Biological Products
Chengdu Kanghong Biotech
China Aoxing
China Chemical & Pharmaceutical Group
China Food and Drug Administration
China Initiative for Diabetes Excellence
China National Accord
China National Biotec Group
China National Medicines
China NT Pharma Group
China OTC Association
China Pharmaceutical Commerce Association
China Pharmaceutical Quality Management Association
China Resources
China Resources Double Crane Pharmaceutical
China Resources Saike
China Resources Sanjiu Medical & Pharmaceutical
China Sky One Medical
ChinaBio Group
ChinaGate
Chinese Academy of Medical Sciences
Chinese Academy of Sciences
Chinese Centre for Disease Control and Prevention
Chinese Diabetes Society
Chinese Ministry of Commerce
Chinese Ministry of Health
Chinese Ministry of Labor and Social Security
Chinese National Development and Reform Commission
Chonqqing Taiji Industry
Cipla
Cord Blood America
Covance
Crown Bioscience
CSPC (China Shijiazhuang Pharmaceutical Group)
Daiichi Sankyo
Dalian Hissen Bio-Pharm
Dawnrays
Denosim
Diapin Therapeutics
Dr. Reddy's Laboratories
Egret
Eisai
Eli Lilly
Engerix-B
Epitomics
European Union (EU)
Excel PharmaStudies
FeRx
First Affiliated Hospital of Sun Yat-sen University
Food and Drug Administration (US FDA)
Foshan Chanberde Development
Fosun Pharma
Frontage Laboratories
Fujifilm Corporation
Fujifilm tissue engineering (Shanghai)
Fuzhou Fuxing Pharmaceutical
Gan & Lee Pharmaceuticals
GeneScience Pharmaceuticals
Genor Biomanufacturing
Genzyme
Gilead Sciences
GlaxoSmithKline (GSK)
Greater China Corporation
Guangdong BeiKang Pharmaceutical
Guangdong Techpool
Guangzhou Baiyunshan Pharmaceutical
Guangzhou Institute of Biomedicine and Health
Guangzhou Medical University
Guangzhou Pharmaceutical
Guizhou Baiqiang Pharmaceutical
Hainan Litzman Pharmaceutical
Hangzhou Jiuyuan Gene Engineering
Hangzhou Sanofi-Synthelabo Minsheng
Hangzhou Tigermed Consulting
Hangzhou Zhongmei Huadong Pharmaceutical
Harbin Pharmaceutical Group
Harvard University
HD Biosciences
Hengrui
Henlius Biopharmaceuticals
HitGen
Hualan Biological Engineering
Hualida Biotech
Huangdon Medicine
Hutchison MediPharma
i3 Research
ICON
Illumina
Inner Mongolia Yili Energy
Innovent Biologics
Institute for BioMedical Research Beijing
Isotechnika Pharma
Ivax
Japan Tissue Engineering Co. Ltd
Jiangsu Chia Tai Tianqin
Jiangsu Hansen Pharmaceutical
Jiangsu Hansoh Pharmaceutical
Jiangsu Hengrui Medicine
Jiangsu New Medicine Research Institution
Jiangsu Walvax Biotech
Jin Chuang
Johnson & Johnson
Joincare Pharma
JOINN Laboratories
Jointown
Kanda Biotechnology
Kangmei Pharmaceutical
Kunming Baker Norton Pharmaceutical
Le Ren Tang Pharmaceutical Group
Lepu Medical
Livzon Pharmaceutical Group
Lundbeck
Massachusetts Institute of Technology (MIT)
McKesson
McNerney & Partners
Medigen Biotechnology Corporation
Merck & Co.
Microport Medical
MicuRx Pharmaceuticals
Mindray
Ministry of Science and Technology
Minsheng Pharmaceutical
Mirahi Biotech
Morgan Stanley
Mycenax
Mylan
Nanjing Hailing National Engineering Research Center
Nanjing Kanghai Pharmaceutical
Nanjing MeiRui Pharma
Nanjing Pharma
Nanjing Pharmaceutical Factory
Natco Pharma
National Institute for the Control of Pharmaceutical and Biological Products
Nestle
Netherlands Organization for Applied Scientific Research
NeuroVive
Newsummit Biopharma
North China Pharmaceutical Group
Northeast General Pharmaceutical
Northeast Pharmaceutical Group (NEPG)
Novartis
Novast Labs
Novo Nordisk
Organisation for Economic Co-operation and Development
Orion
Otsuka
Ouyi Pharma
Pacific MeinuoKe
Panion & BF Biotech
Parexel
Peking University Third Hospital
People for the Ethical Treatment of Animals
Pfizer
Pharmaceutical Product Development LLC (PPD)
Pharmaron
PRA International
Pro Top & Mediking
Psyma Business Research China
Qilu Antibiotics
Qilu Pharmaceutical
QRxPharma
Quintiles
Regeneron
Roche
Sanofi
Servier
Shandong Dong-E E-Jiao
Shandong Kexing Bioproducts
Shandong Xinhua
Shanghai BravoBio
Shanghai Celgen Bio-Pharmaceuticals
Shanghai ChemExplorer
Shanghai Clinical Research Centre
Shanghai CP Guojian Pharmaceuticals
Shanghai Fosun
Shanghai Furen
Shanghai Greenvalley Pharmaceutical
Shanghai Institute for Biological Sciences
Shanghai Institute of Materia Medica
Shanghai Institutes of Biological Sciences
Shanghai Jinhe Bio-Technology
Shanghai MengKe Pharmaceuticals
Shanghai Pharmaceuticals
Shanghai Qisheng
Shanghai Schering-Plough
Shanghai Zhangjiang Biomedical Industry Venture Capital
ShangPharma
Shantou Institute of Ultrasonic Instruments
Shenzhen Kangtai Biological Products
Shenzhen Kangzhe Pharmaceutical
Shenzhen Neptunus Bioengineering
Shenzhen Salubris Pharmaceuticals
Shenzhen SiBiono GeneTech
Shenzhen Wenle ('Main Luck') Pharmaceutical
Shihuida
Shijiazhuang Pharmaceutical Group
Shijiazhuang Yiling
Shire
SiBiono
Sichuan Jiufeng Pharmaceutical
Sichuan Kelun Pharmaceutical
Sichuan Medicine
Sicor
Simcere
SiniWest Holdings
Sino Biological
Sinopharm
Sinovac Biotech
Sirona Biochem
State Key Lab of Respiratory Disease
State Population and Family Planning Commission
State Quality Control Administration
State Traditional Chinese Medicine Administration
Sundiro Pharma
Sunway Biotech
Suzhou Novartis Pharma
Swiss Re
Symbio Pharmaceuticals
Takeda
Tangshan Yian Bioengineering
Tasly Pharmaceutical
Teleos Consulting
Teva Pharmaceutical Industries
The Genome Institute
The United Laboratories
Thermo Fisher Scientific
Tianjin International Joint Academy of Biotechnology and Medicine
Tianjin Jin Yao Group
Tianjin KingYork Group
Tianjin Kinnovata Pharmaceutical
Tianjin Medical University Cancer Hospital
Tianjin Pharmaceuticals Group Corporation (TJPC)
Time Medical Systems
Tonghua Dongbao
Tongrentang Pharmaceutical
Tsinghua University of Beijing
Twinrix
UNICEF
United Pharmatech
University of Michigan
Vectura Group
Ventac Partners
Venturepharm Laboratories
Vertex Pharmaceuticals
Vinise Pharmaceutical
Viva Biotech
Wanbang Biopharmaceuticals
Washington University
Winteam Pharmaceutical Group
World Health Organization (WTO)
World Trade Organization (WHO)
Wuhan National Bioindustry
WuXi AppTec
Xiamen Amoytop Biotech
Xinshengyuan Pharmaceutical Group
Xiuzheng Pharmaceutical Group
Xizang Haisco
Yabao Pharma
Yangtze Pharmaceuticals
Yangtze River Pharmaceutical Group
Youcare Pharmaceutical Group
Yunnan Baiyao
Zendex Bio Strategy Inc
Zensun (Shanghai) Sci & Tech
Zhangjiang Biotech
Zhejiang Beta Pharma
Zhejiang Chiral Medicine
Zhejiang Hisun Pharmaceutical
Zhejiang Huahai Pharmaceutical
Zhejiang Medicine
Zhejiang Tianyuan
Zhongnuo Pharmaceutical
Zhuhai United States Labs
Zuelig Pharma China

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com